2023
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg S. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 240-251. PMID: 37806385, PMCID: PMC11364167, DOI: 10.1016/j.jtho.2023.10.001.Peer-Reviewed Original ResearchProgression-free survivalEGFR-mutant NSCLCTP53 mutationsOverall survivalClinical outcomesEGFR-TKIInferior outcomesWorse outcomesYale cohortMetastatic EGFR-mutant NSCLCShorter progression-free survivalEGFR-mutant lung cancerTyrosine kinase inhibitor therapyFirst-line TKIYale Cancer CenterSecond-line therapyInferior clinical outcomesSubset of patientsKinase inhibitor therapyAdditional therapeutic interventionsAggressive disease phenotypeCo-occurring alterationsTumor suppressor gene alterationsTumor genomic profilingMultiple tumor suppressor genes
2021
Putting the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization Into Practice A Case Series
Bittl J, Bangalore S, DiMaio J, Grant M, Lawton J, Holland J. Putting the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization Into Practice A Case Series. JACC Case Reports 2021, 4: 31-35. PMID: 35036940, PMCID: PMC8743811, DOI: 10.1016/j.jaccas.2021.09.025.Peer-Reviewed Original ResearchACC/AHA/SCAI GuidelineCoronary artery revascularizationArtery revascularizationCase seriesStable ischemic heart diseaseA Case SeriesOptimal medical therapyComplex coronary diseaseSubset of patientsIschemic heart diseaseCardiovascular eventsVentricular dysfunctionCoronary diseaseMedical therapyHeart diseaseRevascularizationDiseaseGuidelinesPatientsDysfunctionTherapyMortalitySelecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nature Reviews Clinical Oncology 2021, 18: 625-644. PMID: 34168333, DOI: 10.1038/s41571-021-00520-1.Peer-Reviewed Original ResearchConceptsSubset of patientsTreatment landscapeRegimen selectionTumor cell PD-L1 expressionChemotherapy-immunotherapy combinationsImmune checkpoint inhibitorsTreatment-naive patientsFirst-line therapyPD-L1 expressionCurrent treatment landscapeCell lung cancerAbsence of headCurrent treatment paradigmsPivotal clinical trialsLong-term efficacyNovel therapeutic strategiesImmunotherapy regimenMetastatic NSCLCImmunotherapeutic strategiesClinicopathological factorsPD-1PD-L1Durable efficacyHistological subtypesLung cancer
2019
Impact of Preoperative Erythropoietin on Allogeneic Blood Transfusions in Surgical Patients
Cho B, Serini J, Zorrilla-Vaca A, Scott M, Gehrie E, Frank S, Grant M. Impact of Preoperative Erythropoietin on Allogeneic Blood Transfusions in Surgical Patients. Anesthesia & Analgesia 2019, Publish Ahead of Print: &na;. PMID: 30649068, DOI: 10.1213/ane.0000000000004005.Peer-Reviewed Original ResearchConceptsRed blood cell transfusionAllogeneic blood transfusionBlood cell transfusionAllogeneic red blood cell transfusionPerioperative allogeneic blood transfusionBlood transfusionPreoperative erythropoietinCell transfusionThromboembolic eventsPatient blood management programPreoperative erythropoietin administrationSubset of patientsBlood management programPerioperative hemoglobin levelsErythropoietic stimulating agentsLength of stayErythropoietin useSecondary outcomesSurgical patientsThromboembolic complicationsBlood lossPrimary outcomeHemoglobin levelsRisk of exposureInpatient hospitalization